Stock info Galapagos | Filter  Basic-Info

Stock: Galapagos (NL Amsterdam Midcap), ISIN: BE0003818359

Last Price 30.75 Max Price 41.55
Min Price 30.75 1 Year return -37.53
Avg. Target 41.50 Expected Return 34.96 %
Sector Health Care Subsector Biotechnology
Sell 0 Rating Star full 12x12Star full 12x12Star half 12x12
Hold 3 Concensus Cons hold
Buy 0
Annual report 2018

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. From the start, Galapagos has operated a hybrid business model, combining internal discovery programs with service activities. The joint venture operated until 2002 when the Company raised €23.4 million in a private placement. In May 2005, the Company raised €22.4 million through its initial public offering on the Euronext Brussels (Ticker symbol: GLPG) and Euronext Amsterdam (GLPGA) stock exchanges. In October 2005, Galapagos acquired BioFocus, a drug discovery company based in Saffron Walden, UK, through an all share offer, giving BioFocus shareholders a 29% state holding in the enlarged Company. (ISIN: BE0003818359 / Mnemo: GLPG)

Loading...

Galapagos in short


This is a Belgo-Dutch company that deals in pharmaceutical research. Galapagos was formed in the years 1999 and is currently situated in Mechelen in Belgium, it also has other locations such as Basel, Zagreb, Leiden and Romainville. The foundation of Galapagos is found in the collaboration between Tibotec and Crucel, which gave it the present name, also, the company is currently manned by a Dutch CEO by the name; Onno van de Stolpe.

Galapagos main operations are centered in the production of drugs used for treatment of diseases such as Cystic fibroids, ulcerative colitis, rheumatoid arthritis and systemic lupus erythematous.

The company research activities are technologically based, these research focuses on adenoviruses which are used to put the sequences of human genes into various cells for purposes of kicking in or out specific kinds of proteins. Some of the drugs currently being developed by the company are GPR84-inhibitor and Filgotinib. Filgotinib will mostly be sold to customers who needs treatment of Crohn's disease and Rheumatoid arthritis, which primarily affects the joints. The company is also presently conducting an intensive research that is focused at production of drugs that can be used to by people with inflammatory bowel related disease conditions.

Galapagos is a multinational biotech corporation focused on developing novel medicines. Galapagos is headquartered in Belgium. the Company provides employment to around 800 people and also reported a revenue of 153 Million in the year 2012. Galapagos established in 1999, which was a joint endeavor between Crucell and Tibotec. From the beginning, Galapagos has functioned on a hybrid business model, uniting domestic discovery plan with service operations. In 2002 the Company reported to raise 23.4 Million Euro in a private placement later in May 2005, the Company during an initial public offering on Euronext Brussels and Amsterdam (ticker symbol: GLPG) raised 22.4 Million Euro.

Galapagos raised another 90 Million Euro through private placements in the year 2006, 2009 and 2010. The company earned additional 4.4 Million Euro in the course of an equity investment by GlaxoSmithKline in 2007. Through an ADR listing, Galapagos started trading in the U.S. OTC market below the ticker symbol GLPYY. Euronext life begins dealing in options for the Galapagos share on 30 April 2013, under the ticker symbol GLS.

In December 2006 Galapagos obtained ProSkelia (France) from ProStrakan by means of an all-share business deal. With ProSkelia, Galapagos gets hold of R&D processed and a portfolio of products aimed at musculoskeletal diseases. Galapagos make a long-term association with leading pharma companies for the research programs. These risks sharing union facilitates Galapagos to put together a pipeline of approximately 30 programs, based mainly on proprietary targets that the corporation has acknowledged. Through this alliance policy, Galapagos is entitled to collect 2 Billion Euros in success reliant objective income plus sovereigns on marketable products. In October 2005 Galapagos obtained BioFocus, which is a drug invention corporation located in Saffron Walden, UK.

Subsequent year, Galapagos acquired Discovery Partners International and UK-based Inpharmatica Ltd. which were drug discovery companies. In 2008, Galapagos acquired Sareum Holdings PLC the structure-based drug discovery company. All these tactical acquisitions facilitate BioFocus to present a full suite of drug discovery products and services.

In February 2010, Galapagos acquired Argenta's service operations. Mutually, Argenta and BioFocus outline one of the world's major drug discovery service organizations, having more than 350 employees & with annual turnover of approximately 70 Million Euros. In January 2013, Galapagos determined to vary the focus of the Zagreb group to external outsourcing, producing a service process called Fidelta. Fidelta has approximately 100 scientists with an average experience of over 11 years in the pharma industry, and more than half of them having a PhD and global experience gained at prominent universities across Europe and the US. BioFocus' proficiency and with drug discovery services and goods has afford a finest spot in the emerging R&D outsourcing market. BioFocus' revenues have grown by 10-15% per annum ever since it was purchased by Galapagos.

Contact info:Street: Generaal De Wittelaan L11 A3Zip Code: 2800 MecheCity: BelgiumCountry: BelgiumPhone: 32 15 34 29 00Email: ir@glpg.comWebsite: www.glpg.com

Sector Review Galapagos

Loading...
Year Turnover Total sector Market share
2019 896 141,925 0.63 %
2020 530 170,231 0.31 %
2021 539 252,886 0.21 %
2022 552 238,500 0.23 %
2023 0 0 0.00 %

Advice Galapagos

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
March 10, 2024 Morgan Stanley Galapagos Hold 35.00 12.14 %
February 01, 2024 KBC Securities Galapagos Buy 55.00 44.09 %
November 29, 2023 Citigroup Galapagos Hold 35.00 12.14 %
November 04, 2023 DeGroof Petercam Galapagos Hold 44.80 31.36 %
June 06, 2023 JP Morgan Galapagos Hold 42.00 26.79 %
May 05, 2023 Jefferies & Co. Galapagos Hold 37.70 18.44 %
October 31, 2023 KBC Securities Galapagos Buy 55.00 44.09 %
August 29, 2023 Citigroup Galapagos Hold 41.00 25.00 %
May 03, 2023 KBC Securities Galapagos Hold 60.00 48.75 %
April 20, 2023 Citigroup Galapagos Buy 51.00 39.71 %
March 02, 2023 Deutsche Bank Galapagos Hold 35.00 6.03 %
February 09, 2023 Bryan Garnier Galapagos Hold 40.00 10.55 %
January 24, 2023 Jefferies & Co. Galapagos Hold 43.70 20.37 %
December 05, 2022 JP Morgan Galapagos Hold 50.00 31.78 %
December 01, 2022 Beleggers Belangen Galapagos Buy
November 16, 2022 Barclays Galapagos Hold 45.00 22.82 %
November 12, 2022 Deutsche Bank Galapagos Hold 40.00 15.62 %
November 05, 2022 KBC Securities Galapagos Hold 60.00 46.32 %
October 15, 2022 Barclays Galapagos Hold 50.00 33.32 %
March 10, 2022 Citigroup Galapagos Buy 67.00 47.94 %
February 10, 2022 Barclays Galapagos Hold 60.00 32.30 %
January 28, 2022 Bryan Garnier Galapagos Buy 65.00 37.22 %
January 27, 2022 Citigroup Galapagos Buy 61.00 31.85 %
November 30, 2021 Barclays Galapagos Hold 48.00 18.90 %
November 12, 2021 UBS Galapagos Hold 52.00 22.71 %
November 08, 2021 Jefferies & Co. Galapagos Hold 53.00 18.83 %
October 05, 2021 Citigroup Galapagos Hold 51.00 16.04 %
October 05, 2021 Goldman Sachs Galapagos Sell 44.00 1.23 %
October 04, 2021 KBC Securities Galapagos Buy 60.00 28.63 %
August 19, 2021 Barclays Galapagos Hold 50.00 -8.08 %
August 12, 2021 Goldman Sachs Galapagos Sell 47.00 -12.17 %
August 11, 2021 JP Morgan Galapagos Hold 60.00 12.13 %
August 09, 2021 Deutsche Bank Galapagos Hold 50.00 -6.20 %
August 08, 2021 Jefferies & Co. Galapagos Hold 56.00 5.18 %
July 28, 2021 Goldman Sachs Galapagos Sell 49.00 -3.43 %
July 26, 2021 Sanford C. Bernstein & Co Galapagos Hold 63.00 19.56 %
July 16, 2021 Bank of America Merrill Lynch Galapagos Hold
July 16, 2021 KBC Securities Galapagos Buy 66.00 18.12 %
June 03, 2021 Goldman Sachs Galapagos Sell 57.00 10.28 %
May 12, 2021 JP Morgan Galapagos Hold 68.00 20.68 %



News Galapagos

Analysts expect over 2023 shrinking sales Galapagos

Tomorrow the Belgian company Galapagos will publish its past quarter results. Over the current book year the company from could achieve a revenue around 521.23 million euros (consensus estimates). This is slightly lower than 2022's revenue of 552.13 million...

Analysts expect over 2021 decreasing revenue Galapagos

Tomorrow the Belgian company Galapagos will publish its past quarters results. For this year the company, located in Malines (Mechelen) revenue will be around 521.67 million euros. This is according to the average of the analysts' estimates. This is slightlylower...

OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

Galapagos NV ( Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 is a Phase...

Analysts count on sales decrease Galapagos

Tomorrow the Belgian Galapagos will report its past quarters results. Over the current book year the total revenue from the company in Malines (Mechelen) will be 557,98 million euros (consensus estimates). This is rather significant lower than 2019's revenueof...

Galapagos strong outperformer biotech sector

In the recent years Galapagos was very succesful for investors. Because of the massive return over the past 10 years of 1061 percent the share belongs to the top of the biotech companies. Shares of the sector yielded the past 10 years a gain of at around 241 percent....

Annual reports Galapagos

2017 2018 2019 2020 2021

Profile Galapagos

Galapagos

(BE0003818359)/ GLPG

Galapagos has it' headquarter based in Belgium. The company mostly operates in the biotech sector. The period from 2006 till the end of 2016 the international sector gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year was a good year for Galapagos investors

Over the past year the company' stock gained around 9 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 377 percent. Galapagos's revenues between 2011 and 2015 were very volatile through the time and moved between 152,98 million euros and 60,58 million euros. Galapagos's net results between 2011 and 2015 were quite unstable and moved between -30,06 million euros and -118,41 million euros.

Over the past 5 years the Belgian company paid out dividends.

At the end of 2015 Galapagos employed at around 417 people.

Quite a lot of debt Galapagos

At the end of 2015 the biotech company's balance sheet was worth 442,51 million euros. Of the total balance sheet 77,51 million euros (17,52 percent) was financed by debt. As per the end of 2015 Galapagos's price/earnings-ratio equaled -5. So investors paid for 1 stock -5 times the earnings per share of 2015. Based on the classical stock valuation theories the Belgian stock can be seen as a value stock.

At the end of 2015 the Belgian company's market capitalization equaled around 1,99 billion euros. At the end of 2015 the Belgian company had around 35,7 million stocks listed.

All Galapagos's financial reports are available here. More information about Galapagos can be found it's website. .


Results Galapagos

Results
2015
2016
2017
2018
2019
2020
Revenue
61
152
156
318
896
530
Costs
179
98
272
347
746
836
Profit
-118
54
-116
-29
150
-305
Margin of profit
-195.46
35.62
-74.20
-9.21
16.73
-57.60
ROI
-32.44
7.12
-11.43
-2.41
5.21
-11.44

Balance Galapagos

Balance
2015
2016
2017
2018
2019
2020
Equity
365
759
1,012
1,214
2,876
2,670
Debt
78
325
274
225
3,193
3,047
Total assets
443
1,083
1,286
1,440
6,069
5,718
Solvency
82.48
70.03
78.68
84.35
47.39
46.70
Cash
349
973
1,151
1,291
5,781
5,161
Cashflow
-115
239
-147
-142
3,010
-427
Employees
435
508
600
725
0
Revenue per employee
0.14
0.30
0.26
0.44
0.0
Cashflow / Debt
-1.48
0.74
-0.54
-0.63
0.94
-0.14

Details Galapagos

Details
2016
2017
2018
2019
2020
Price
56.76
60.94
78.98
80.56
186.50
Eps
1.14
-2.34
-0.56
2.49
-4.69
Price/earnings-ratio
49.79
-26.04
-141.04
32.35
-6.56
Dividend
0.0
0.0
0.0
0.0
Dividend %
0.00 %
0.00 %
0.00 %
0.00 %
Payout %
0.0
0.0
0.0
0.0
Book value
16.40
19.87
22.29
44.47
40.82
Market to book
0.29
0.33
0.28
0.55
1.33
Cashflow per stock
5.18
-2.89
-2.62
46.54
-6.53
Stocks
46
51
54
65
65
Market Cap
2.625.50
3.104.09
4.301.68
5.209.56
2.011.41

Dividend Galapagos


Price info Galapagos

Date
Price
22 Mar 2024
30.75
18 Mar 2024
30.99
15 Mar 2024
31.53
12 Mar 2024
31.78
11 Mar 2024
31.65
09 Mar 2024
31.65
07 Mar 2024
31.65
01 Mar 2024
32.89
29 Feb 2024
33.70
27 Feb 2024
33.98
22 Feb 2024
35.39
21 Feb 2024
36.61
20 Feb 2024
36.81
15 Feb 2024
36.11
14 Feb 2024
36.49
13 Feb 2024
36.49
09 Feb 2024
35.78
08 Feb 2024
35.78
07 Feb 2024
35.99
06 Feb 2024
35.08
05 Feb 2024
34.54
01 Feb 2024
34.87
31 Jan 2024
34.87
30 Jan 2024
35.21
27 Jan 2024
35.07
25 Jan 2024
35.32
24 Jan 2024
35.13
23 Jan 2024
34.80
16 Jan 2024
35.36
11 Jan 2024
36.86